July 7, 2022
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) scored sales of 13.1 billion yen on an NHI price basis in June, capturing the top-selling title in the Japan drug market for the sixth consecutive month, according to a monthly snapshot report released...read more